全文获取类型
收费全文 | 71395篇 |
免费 | 5930篇 |
国内免费 | 4518篇 |
专业分类
耳鼻咽喉 | 509篇 |
儿科学 | 1804篇 |
妇产科学 | 850篇 |
基础医学 | 13487篇 |
口腔科学 | 1421篇 |
临床医学 | 6640篇 |
内科学 | 10394篇 |
皮肤病学 | 1011篇 |
神经病学 | 4506篇 |
特种医学 | 1813篇 |
外国民族医学 | 32篇 |
外科学 | 3680篇 |
综合类 | 14070篇 |
现状与发展 | 28篇 |
一般理论 | 1篇 |
预防医学 | 4622篇 |
眼科学 | 1266篇 |
药学 | 5603篇 |
19篇 | |
中国医学 | 1655篇 |
肿瘤学 | 8432篇 |
出版年
2024年 | 135篇 |
2023年 | 829篇 |
2022年 | 1569篇 |
2021年 | 2399篇 |
2020年 | 2170篇 |
2019年 | 1972篇 |
2018年 | 1826篇 |
2017年 | 2029篇 |
2016年 | 2361篇 |
2015年 | 2457篇 |
2014年 | 3813篇 |
2013年 | 4757篇 |
2012年 | 3931篇 |
2011年 | 4741篇 |
2010年 | 3828篇 |
2009年 | 3869篇 |
2008年 | 4137篇 |
2007年 | 4374篇 |
2006年 | 4140篇 |
2005年 | 3881篇 |
2004年 | 3491篇 |
2003年 | 3046篇 |
2002年 | 2656篇 |
2001年 | 2417篇 |
2000年 | 2010篇 |
1999年 | 1681篇 |
1998年 | 1479篇 |
1997年 | 1226篇 |
1996年 | 895篇 |
1995年 | 783篇 |
1994年 | 615篇 |
1993年 | 406篇 |
1992年 | 339篇 |
1991年 | 274篇 |
1990年 | 242篇 |
1989年 | 161篇 |
1988年 | 141篇 |
1987年 | 119篇 |
1986年 | 79篇 |
1985年 | 137篇 |
1984年 | 100篇 |
1983年 | 65篇 |
1982年 | 67篇 |
1981年 | 56篇 |
1980年 | 47篇 |
1979年 | 29篇 |
1978年 | 13篇 |
1977年 | 8篇 |
1976年 | 10篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Cancer cell》2022,40(8):835-849.e8
- Download : Download high-res image (220KB)
- Download : Download full-size image
3.
目的探讨脊髓小脑共济失调2型(SCA2)致病基因ATXN2异常等位基因中间重复个体的表型和分子遗传学特点。方法针对2005—2018年中日友好医院神经科运动障碍与神经遗传病研究中心收集的1383个常染色体显性遗传共济失调家系的先证者和部分家系成员,采用荧光标记毛细管电泳片段分析方法进行动态突变检测,对携带ATXN2基因中间重复的个体进行临床表型和遗传特征分析。结果共检出163个家系(包含先证者和家系成员共203人)携带异常扩展的ATXN2基因CAG重复序列,其中93个家系中有107例的异常扩展等位基因重复次数在29~34次之间。在其中的20个亲子对中,父系遗传16个,异常等位基因的代间扩展增加0~28次,母系遗传4个,异常等位基因的代间扩展增加0~4次。结论对于临床拟诊SCA2家系患者,需对其亲代或成年子代个体进行ATXN2基因检测,以免漏诊。动态突变基因检测有助于识别中间重复的个体,对明确家系致病基因和遗传咨询至关重要。 相似文献
4.
5.
[摘要]?目的?结合环介导等温扩增技术(loop-mediated isothermal amplification, LAMP)和微流控芯片技术,建立一种适合现场快速检测登革病毒的方法。方法?利用RT-LAMP,针对登革病毒基因组中3’非编码区中特异性序列进行扩增,建立基于微流控芯片技术的LAMP检测方法,优化检测体系,并对该方法的灵敏性和特异性进行评估。结果?基于LAMP 和微流控芯片技术的登革病毒检测方法,通过对病毒模板进行扩增,发现与其他病毒无交叉反应,特异性良好;同时,结果显示该方法对登革病毒检测灵敏性可达61.2 pg/μl,与实时荧光定量PCR仪所达到的检测灵敏性一致。结论?基于LAMP和微流控芯片技术的登革病毒检测方法具有操作简单、快速、对设备要求低等优势,并且灵敏性、特异性均较好,是一种便于开展现场快速检测的方法。 相似文献
6.
7.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
8.
《Archivos de bronconeumología》2022,58(5):406-411
IntroductionLung cancer (LC) is usually diagnosed at advanced stages with only a 12% 5-year survival. Trials as NLST and NELSON show a mortality decrease, which justifies implementation of lung cancer screening in risk population. Our objective was to show survival results of the largest LC screening program in Spain with low dosage computed tomography (LDCT).MethodsClinical records from International Early Lung Cancer Detection Program (IELCAP) at Valencia, Spain were analysed. This program recruited volunteers, ever-smokers aged 40-80 years, since 2008. Results are compared to those from other similar sizeable programs.ResultsA total of 8278 participants were screened with at least two-rounds until November 2020. A mean of 6 annual screening rounds were performed. We detected 239 tumours along 12-year follow-up. Adenocarcinoma was the most common histology, being 61.3% at stage I. The lung cancer prevalence and incidence proportion was 1.5% and 1.4%, respectively with an annual detection rate of 0.17. One-year survival and 10-year survival were 90% and 80.1%, respectively. Adherence was 96.84%.ConclusionLargest lung cancer screening in Spain shows that survival is improved when is performed in multidisciplinary team experienced in management of LC, and is comparable to similar screening programs. 相似文献
9.
10.